CPT code 81212: BRCA testing, three specified variants2026 Medicare lab fee · Clinical Laboratory Fee Schedule

Targeted analysis detects three specified BRCA1 and BRCA2 variants to help assess inherited breast and ovarian cancer risk.

CMS CLFS 2026 Q4Effective Oct 1, 2026Same amount nationwide51 Medicare services in 2024

Medicare pays $440.00 for 81212 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.

Medicare lab fee · CLFS 2026 Q4

National CLFS amount

$440.00

In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.

Geographic adjustment
None
Office vs facility
Same
Since 2020
Unchanged
CMS updates
Quarterly

Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.

On this page 8 sections
  1. Medicare lab fee
  2. What 81212 covers
  3. How it’s paid
  4. Amount history
  5. Similar tests
  6. Related codes
  7. Billing questions
  8. Sources

What 81212 covers

This molecular genetic test looks for BRCA1 variants 185delAG and 5385insC, and BRCA2 variant 6174delT. These variants are associated with hereditary breast and ovarian cancer. Clinicians may order the targeted assay when evaluating inherited cancer risk, including when a patient’s history or ancestry makes testing for these particular variants relevant. Molecular laboratories perform and report the genetic analysis; oncology, primary care, and genetics professionals may order it as part of risk assessment.

Report this code for the assay covering the three specified variants, not as a full analysis of either gene. Medicare pays the test only through the Clinical Laboratory Fee Schedule. The 2026 national CLFS amount is $440.00, unchanged since 2020; the same amount applies across localities, with no office-versus-facility difference. The test is excluded from the physician fee schedule.

This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.

How Medicare pays 81212

Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.

One national amount

CMS sets a single Clinical Laboratory Fee Schedule amount for 81212. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.

No office or facility rate

Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.

Updated every quarter

CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.

Excluded from the physician fee schedule

The physician fee schedule lists 81212 with status X (excluded by statute), so the test itself is paid only from the CLFS.

81212 on the lab fee schedule since 2020

81212 · CLFS 2026 Q4 (current)

$440.00

Unchanged since Jan 1, 2020

Amount in each year’s latest CLFS release · bars start at $0

27 quarterly CLFS releases on file, first CLFS 2020 Q1. A code missing from a quarter wasn’t on that release.

81212 compared with similar tests

81215BRCA1 testingKnown familial variant$375.25
Choose 81215 for analysis of a known familial BRCA1 variant. Code 81212 covers two specified BRCA1 variants and one specified BRCA2 variant.
81216BRCA2 sequencingFull gene sequence$185.12
Code 81216 is for full BRCA2 sequence analysis. Code 81212 is limited to BRCA2 variant 6174delT and two specified BRCA1 variants.
81217BRCA2 testingKnown familial variant$375.25
Choose 81217 for a known familial BRCA2 variant. Code 81212 tests BRCA2 6174delT along with two specified BRCA1 variants.

81212 billing questions

How does this differ from BRCA1 or BRCA2 familial-variant testing?

This code covers three specified variants across both genes. Codes 81215 and 81217 are for a known familial variant in BRCA1 and BRCA2, respectively.

Is this a full BRCA gene analysis?

No. It targets only BRCA1 185delAG and 5385insC and BRCA2 6174delT. Full BRCA2 sequencing is represented by code 81216.

Which variants does this code cover?

It covers BRCA1 185delAG and 5385insC, plus BRCA2 6174delT.

Does Medicare pay this through the physician fee schedule?

No. Medicare pays this test through the CLFS only, at one national amount that applies across localities and settings.

Where this amount comes from

FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.

CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027

Show the CMS file line behind this amount
CLFS row for 81212PUF_CLFS_CY2026_Q4V1.csv, line 808 (CLFS 2026 Q4)

Open CMS sourceHow we source rates

Did this answer your question about what Medicare pays for 81212?

Tell us what you were actually trying to work out. We’ll answer you directly, or build the page that does.

Fee sheets · Coming soon

Put 81212 and the rest of your codes on one sheet

Your codes at your locality, with payer contracts beside Medicare.

Join the waitlist